Back to Agenda
The Cost of Moving the Needle on Clinical Trial Representation: Strategies for Diversity Budget Planning and Resourcing
Session Chair(s)
Lloryn Hubbard
Head of Patient Diversity
PPD Part of Thermo Fisher Scientific, United States
Evidence shows that improving diversity in clinical trials requires early planning. The session presents a cost analysis and case examples from an expert panel on the impact of incorporating patient diversity tactics and resources early in the process.
Learning Objective : Discuss how to quantify the cost and resources required to execute tactics that increase clinical trial diversity; Explain how the exclusion of patient diversity tactics in budget planning impacts diversity and overall study milestones; Identify considerations that can influence leadership decision-making around diversity during the budget planning process.
Speaker(s)
Industry Update
Ryan Brown, MPA
H1, United States
Regional Vice President, Trial Landscape
Industry Update
Steve T. Satek, MBA
Flourish Research, United States
Executive Vice President
Industry Update
Monica Eason
Genentech, A Member of the Roche Group, United States
Clinical Operations Portfolio Leader
Have an account?